{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:00:41Z","timestamp":1781632841296,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colon cancer, characterized by high incidence and mortality, faces clinical challenges due to high recurrence rates and drug resistance. Aberrant activation of Hedgehog (Hh) signaling pathway is a key driver of colon cancer progression, making it a promising therapeutic target; however, current Hh inhibitors are limited by resistance and adverse effects. Drug repurposing offers a strategic alternative to accelerate oncology drug development. Oliceridine (TRV130) is a clinically approved, selective \u00b5-opioid receptor agonist with a well-established safety profile for pain management. Notably, its potential anti-tumor activity and impact on oncogenic pathways like Hh signaling remain entirely unexplored. This study aims to investigate the anti-colon cancer efficacy of TRV130 and its underlying mechanisms, focusing on the Hh pathway, thereby evaluating its repurposing potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To establish the rationale for targeting the Hh pathway and the novelty of investigating TRV130, a focused literature review was conducted using PubMed and Web of Science databases (search period: 2000\u20132023), employing keywords including \u201ccolon cancer,\u201d \u201cHedgehog pathway,\u201d \u201cdrug repurposing,\u201d and \u201cTRV130\/Oliceridine.\u201d Based on this foundational evidence, the anti-tumor effects of TRV130 were systematically evaluated. Cell proliferation was assessed via MTT, EdU, and colony formation assays. Apoptosis was evaluated by flow cytometry and TUNEL assays. Migration and invasion were analyzed by Transwell and wound healing assays. The expressions of Cyclin D1, Bcl-2, Caspase 3, and Hh pathway proteins (PTCH1, GLI1) were detected by Western blot. A subcutaneous xenograft model was established in nude mice using HCT116 cells to validate in vivo efficacy, with tumor tissues analyzed by immunohistochemistry (IHC) and Western blot.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TRV130 exhibited potent, dose-dependent inhibition of colon cancer cell proliferation, migration, and invasion. It induced apoptosis through both intrinsic and extrinsic pathways, as evidenced by the downregulation of Cyclin D1 and Bcl-2, and the upregulation of cleaved caspase 3. Mechanistically, TRV130 significantly suppressed the Hh signaling pathway, reducing the expression of its key effectors (GLI1 and PTCH1) to an extent comparable to cyclopamine (Cyc), a canonical Hh inhibitor. In vivo, TRV130 administration dose-dependently inhibited tumor growth in xenograft models, reducing both tumor volume and weight. IHC and Western blot analyses of tumor tissues confirmed the downregulation of Hh pathway proteins and pro-proliferative markers, alongside upregulation of apoptotic markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identifies TRV130 as a novel inhibitor of the Hh pathway, demonstrating its significant anti-colon cancer effects in vitro and in vivo. These findings reveal a previously unexplored, oncological mechanism for this clinically safe drug and support its repurposing as a promising therapeutic candidate, potentially offering an alternative to current Hh-targeted therapies. This work provides the foundational evidence for further development of TRV130 against colon cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-026-00633-6","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:54:37Z","timestamp":1768787677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TRV130 inhibits colon cancer progression via suppressing the Hedgehog signaling pathway: in vitro and in vivo evidence"],"prefix":"10.1186","volume":"163","author":[{"given":"Yuanzhao","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changcheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"633_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E, Arnold M. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72:338\u201344.","journal-title":"Gut"},{"key":"633_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.dld.2023.11.041","volume":"56","author":"V Balboa-Barreiro","year":"2024","unstructured":"Balboa-Barreiro V, P\u00e9rtega-D\u00edaz S, Garc\u00eda-Rodr\u00edguez T, et al. Colorectal cancer recurrence and its impact on survival after curative surgery: an analysis based on multistate models. Dig Liver Dis. 2024;56:1229\u201336.","journal-title":"Dig Liver Dis"},{"key":"633_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lddd.2025.100082","volume":"22","author":"P Lv","year":"2025","unstructured":"Lv P, Ren B, Cheng G. Ginsenoside Rh3 suppresses cell proliferation, metastasis, and oxidative stress of colorectal cancer via targeting HSP90AA1. Lett Drug Des Discov. 2025;22:100082.","journal-title":"Lett Drug Des Discov"},{"key":"633_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/OTT.S150367","volume":"11","author":"H Chang","year":"2018","unstructured":"Chang H, Yu X, Xiao WW, et al. Neoadjuvant chemoradiotherapy followed by surgery in patients with unresectable locally advanced colon cancer: a prospective observational study. Onco Targets Ther. 2018;11:409\u201318.","journal-title":"Onco Targets Ther"},{"key":"633_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","volume":"5","author":"Y-H Xie","year":"2020","unstructured":"Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Tar. 2020;5:22.","journal-title":"Signal Transduct Tar"},{"key":"633_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.trecan.2024.05.001","volume":"10","author":"M Singh","year":"2024","unstructured":"Singh M, Morris VK, Bandey IN, Hong DS, Kopetz S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer. 2024;10:598\u2013609.","journal-title":"Trends Cancer"},{"key":"633_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/514738","volume":"2011","author":"CC Wu","year":"2011","unstructured":"Wu CC, Sytwu HK, Lu KC, Lin YF. Role of T cells in type 2 diabetic nephropathy. Exp Diabetes Res. 2011;2011:514738.","journal-title":"Exp Diabetes Res"},{"key":"633_CR8","first-page":"262","volume":"10","author":"N Alasgarova","year":"2025","unstructured":"Alasgarova N, Baran A, Y\u0131ld\u0131ztekin M, Ganbarov D, Babayeva S, G\u00fcne\u015f Z, et al. Synthesis of plant-derived selenium nanoparticles from Lankaran-Astara tea (Camellia sinensis L.) plant and evaluation of their activities on different enzymes. Adv Biol Earth Sci. 2025;10:262\u20139.","journal-title":"Adv Biol Earth Sci"},{"key":"633_CR9","doi-asserted-by":"publisher","first-page":"S855","DOI":"10.1016\/S2221-1691(12)60323-2","volume":"2","author":"SK Arthanari","year":"2012","unstructured":"Arthanari SK, Vanitha J, Ganesh M, Venkateshwaran K, Clercq D. Evaluation of antiviral and cytotoxic activities of methanolic extract of S. grandiflora (Fabaceae) flowers. Asian Pac J Trop Biomed. 2012;2:S855-8.","journal-title":"Asian Pac J Trop Biomed"},{"key":"633_CR10","first-page":"208","volume":"10","author":"M Evcil","year":"2025","unstructured":"Evcil M, Kurt B, Baran A, Mouhoub A, Karakaplan M. Development, characterization and application of chitosan-based formulation incorporating Crataegus orientalis extract for food conservation. Adv Biol Earth Sci. 2025;10:208\u201325.","journal-title":"Adv Biol Earth Sci"},{"key":"633_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12645-024-00285-z","volume":"15","author":"S Montazersaheb","year":"2024","unstructured":"Montazersaheb S, Eftekhari A, Shafaroodi A, et al. Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC). Cancer Nanotechnol. 2024;15:47.","journal-title":"Cancer Nanotechnol"},{"key":"633_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1482130","volume":"15","author":"C \u00d6zi\u00e7","year":"2024","unstructured":"\u00d6zi\u00e7 C, Erta\u015f E, Baran MF, et al. Synthesis and characterization of activated carbon-supported magnetic nanocomposite (MNPs-OLAC) obtained from okra leaves as a nanocarrier for targeted delivery of morin hydrate. Front Pharmacol. 2024;15:1482130.","journal-title":"Front Pharmacol"},{"key":"633_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/ph17060772","volume":"17","author":"A Baran","year":"2024","unstructured":"Baran A, Erta\u015f E, Baran MF. Green-synthesized characterization, antioxidant and antibacterial applications of CtAC\/MNPs-Ag nanocomposites. Pharmaceuticals (Basel). 2024;17:772.","journal-title":"Pharmaceuticals (Basel)"},{"key":"633_CR14","first-page":"347","volume":"10","author":"U Yaman","year":"2025","unstructured":"Yaman U, Ince-Erguc E, Ozturk I, Okudan ES. Evaluation of cytotoxic and antimicrobial activities of methanolic extracts from cystoseira foeniculacea and sargassum vulgare. Adv Biol Earth Sci. 2025;10:347\u201358.","journal-title":"Adv Biol Earth Sci"},{"key":"633_CR15","first-page":"289","volume":"10","author":"S Tumur","year":"2025","unstructured":"Tumur S, Cihan A, Zahir Duz M. Toxic elements (As3+, Pb2+, Hg2+, Cd2+) in wastewater: a case study on environmental threats and health risks. Adv Biol Earth Sci. 2025;10:289\u2013302.","journal-title":"Adv Biol Earth Sci"},{"key":"633_CR16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41573-025-01139-y","volume":"24","author":"JS Lorente","year":"2025","unstructured":"Lorente JS, Sokolov AV, Ferguson G, et al. GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2025;24:458\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"633_CR17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2213140120","volume":"120","author":"J Zhao","year":"2023","unstructured":"Zhao J, DiGiacomo V, Ferreras-Gutierrez M. Small-molecule targeting of GPCR-independent noncanonical G-protein signaling in cancer. Proc Natl Acad Sci USA. 2023;120:e2213140120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"633_CR18","first-page":"245","volume":"10","author":"I Gareev","year":"2025","unstructured":"Gareev I, Pavlov V, Eyvazova K, Mashkin A, Iessa Obeid A, Yang L. Harnessing adrenergic receptor pathways in gliomas: from tumor biology to targeted therapies. Adv Biol Earth Sci. 2025;10:245\u201361.","journal-title":"Adv Biol Earth Sci"},{"key":"633_CR19","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.2147\/DDDT.S525471","volume":"19","author":"K Yi","year":"2025","unstructured":"Yi K, Sun W. Overview and prospects of the clinical application of oliceridine. Drug Des Devel Ther. 2025;19:5415\u201330.","journal-title":"Drug Des Devel Ther"},{"key":"633_CR20","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/jcph.1076","volume":"58","author":"MJ Fossler","year":"2018","unstructured":"Fossler MJ, Sadler BM, Farrell C, et al. Oliceridine (TRV130), a novel G protein-biased ligand at the \u00b5-opioid receptor, demonstrates a predictable relationship between plasma concentrations and pain relief. I: Development of a pharmacokinetic\/pharmacodynamic model. J Clin Pharmacol. 2018;58:750\u201361.","journal-title":"J Clin Pharmacol"},{"key":"633_CR21","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.2147\/DDDT.S475205","volume":"18","author":"C Wang","year":"2024","unstructured":"Wang C, Liu L, Bai X. Global trends in oliceridine (TRV130) research from 2013 to 2024: a bibliometrics and knowledge graph analysis. Drug Des Devel Ther. 2024;18:4681\u201392.","journal-title":"Drug Des Devel Ther"},{"key":"633_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01559-5","volume":"8","author":"J Jing","year":"2023","unstructured":"Jing J, Wu Z, Wang J, et al. Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies. Signal Transduct Target Ther. 2023;8:315.","journal-title":"Signal Transduct Target Ther"},{"key":"633_CR23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.phrs.2019.01.014","volume":"141","author":"A Salaritabar","year":"2019","unstructured":"Salaritabar A, Berindan-Neagoe I, Darvish B, et al. Targeting hedgehog signaling pathway: paving the road for cancer therapy. Pharmacol Res. 2019;141:466\u201380.","journal-title":"Pharmacol Res"},{"key":"633_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02327-w","volume":"11","author":"G Cong","year":"2025","unstructured":"Cong G, Zhu X, Chen XR, Chen H, Chong W. Mechanisms and therapeutic potential of the hedgehog signaling pathway in cancer. Cell Death Discov. 2025;11:40.","journal-title":"Cell Death Discov"},{"key":"633_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10234-9","volume":"10","author":"H Qian","year":"2019","unstructured":"Qian H, Cao P, Hu M, et al. Inhibition of tetrameric Patched1 by Sonic Hedgehog through an asymmetric paradigm. Nat Commun. 2019;10:2320.","journal-title":"Nat Commun"},{"key":"633_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1257173","volume":"11","author":"L Zhang","year":"2023","unstructured":"Zhang L, Zhang Y, Li K, Xue S. Hedgehog signaling and the glioma-associated oncogene in cancer radioresistance. Front Cell Dev Biol. 2023;11:1257173.","journal-title":"Front Cell Dev Biol"},{"key":"633_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/0115665232273077240104045022","volume":"24","author":"S Sriramulu","year":"2024","unstructured":"Sriramulu S, Malayaperumal S, Banerjee A, et al. AEG-1 as a novel therapeutic target in colon cancer: a study from silencing AEG-1 in BALB\/c mice to large data analysis. Curr Gene Ther. 2024;24:307\u201320.","journal-title":"Curr Gene Ther"},{"key":"633_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2021.04.003","volume":"85","author":"J Jiang","year":"2022","unstructured":"Jiang J. Hedgehog signaling mechanism and role in cancer. Semin Cancer Biol. 2022;85:107\u201322.","journal-title":"Semin Cancer Biol"},{"key":"633_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/1389202924666230503122134","volume":"24","author":"F Pang","year":"2023","unstructured":"Pang F, Yang P, Wang T, et al. Comprehensive analysis of alternative polyadenylation events associated with the tumor immune microenvironment in colon adenocarcinoma. Curr Genomics. 2023;24:48\u201361.","journal-title":"Curr Genomics"},{"key":"633_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101174","volume":"14","author":"Y Xi","year":"2021","unstructured":"Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:101174.","journal-title":"Transl Oncol"},{"key":"633_CR31","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1245\/s10434-025-16905-w","volume":"32","author":"Z Zhan","year":"2025","unstructured":"Zhan Z, Chen B, Lin W, et al. Rising burden of colon and rectum cancer in china: an analysis of Trends, gender Disparities, and projections to 2030. Ann Surg Oncol. 2025;32:3361\u201371.","journal-title":"Ann Surg Oncol"},{"key":"633_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101951","volume":"88","author":"H Wu","year":"2023","unstructured":"Wu H, Chen W, Chen Z, Li X, Wang M. Novel tumor therapy strategies targeting endoplasmic reticulum-mitochondria signal pathways. Ageing Res Rev. 2023;88:101951.","journal-title":"Ageing Res Rev"},{"key":"633_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02148-4","volume":"10","author":"Y Li","year":"2025","unstructured":"Li Y, Liu F, Cai Q, et al. Invasion and metastasis in cancer: molecular insights and therapeutic targets. Signal Transduct Target Ther. 2025;10:57.","journal-title":"Signal Transduct Target Ther"},{"key":"633_CR34","doi-asserted-by":"publisher","first-page":"e21923","DOI":"10.1096\/fj.202100099R","volume":"35","author":"P Wang","year":"2021","unstructured":"Wang P, Hua X, Sun Y, et al. Loss of Haspin suppresses cancer cell proliferation by interfering with cell cycle progression at multiple stages. FASEB J. 2021;35:e21923.","journal-title":"FASEB J"},{"key":"633_CR35","doi-asserted-by":"publisher","first-page":"100030","DOI":"10.1016\/j.pharmr.2024.100030","volume":"77","author":"A Glaviano","year":"2025","unstructured":"Glaviano A, Singh SK, Lee EHC, et al. Cell cycle dysregulation in cancer. Pharmacol Rev. 2025;77:100030.","journal-title":"Pharmacol Rev"},{"key":"633_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/07357907.2024.2445528","volume":"43","author":"M Mosadegh","year":"2025","unstructured":"Mosadegh M, Noori Goodarzi N, Erfani Y. A comprehensive insight into apoptosis: molecular mechanisms, signaling pathways, and modulating therapeutics. Cancer Invest. 2025;43:33\u201358.","journal-title":"Cancer Invest"},{"key":"633_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12935-022-02656-1","volume":"22","author":"A Kouroshnia","year":"2022","unstructured":"Kouroshnia A, Zeinali S, Irani S, Sadeghi A. Induction of apoptosis and cell cycle arrest in colorectal cancer cells by novel anticancer metabolites of streptomyces sp. 801. Cancer Cell Int. 2022;22:235.","journal-title":"Cancer Cell Int"},{"key":"633_CR38","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3390\/jcm12020572","volume":"12","author":"SY Jun","year":"2023","unstructured":"Jun SY, Kim J, Yoon N, Maeng LS, Byun JH. Prognostic potential of cyclin D1 expression in colorectal cancer. J Clin Med. 2023;12:572.","journal-title":"J Clin Med"},{"key":"633_CR39","doi-asserted-by":"publisher","first-page":"12483","DOI":"10.1093\/nar\/gkaa1002","volume":"48","author":"S Hume","year":"2020","unstructured":"Hume S, Dianov GL, Ramadan K. A unified model for the G1\/S cell cycle transition. Nucleic Acids Res. 2020;48:12483\u2013501.","journal-title":"Nucleic Acids Res"},{"key":"633_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/CAD.0000000000001553","volume":"35","author":"L Wang","year":"2024","unstructured":"Wang L, Xi C, Liu R, et al. Dual targeting of Mcl-1 and Bcl-2 to overcome chemoresistance in cervical and colon cancer. Anticancer Drug. 2024;35:219\u201326.","journal-title":"Anticancer Drug"},{"key":"633_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02176-0","volume":"10","author":"M Vogler","year":"2025","unstructured":"Vogler M, Braun Y, Smith VM, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal Transduct Target Ther. 2025;10:91.","journal-title":"Signal Transduct Target Ther"},{"key":"633_CR42","doi-asserted-by":"publisher","first-page":"29227","DOI":"10.1039\/D1RA03820F","volume":"11","author":"T Adon","year":"2021","unstructured":"Adon T, Shanmugarajan D, Kumar HY. CDK4\/6 inhibitors: a brief overview and prospective research directions. RSC Adv. 2021;11:29227\u201346.","journal-title":"RSC Adv"},{"key":"633_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal CL, Jongbloed EM, Wilting SM, et al. Inhibiting CDK4\/6 in breast cancer with Palbociclib, Ribociclib, and Abemaciclib: similarities and differences. Drugs. 2021;81:317\u201331.","journal-title":"Drugs"},{"key":"633_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2174\/1573394718666220822175032","volume":"19","author":"A Omar","year":"2023","unstructured":"Omar A, Ruff P, Penny C. Inhibition of the sonic hedgehog pathway using small molecule inhibitors: targeting colon cancer stem cells. Curr Cancer Ther Rev. 2023;19:138\u201355.","journal-title":"Curr Cancer Ther Rev"},{"key":"633_CR45","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/cells7110208","volume":"7","author":"IN Sari","year":"2018","unstructured":"Sari IN, Phi LTH, Jun N, et al. Hedgehog signaling in cancer: A prospective therapeutic target for eradicating cancer stem cells. Cells. 2018;7:208.","journal-title":"Cells"},{"key":"633_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm5563","volume":"8","author":"M Kinnebrew","year":"2022","unstructured":"Kinnebrew M, Woolley RE, Ansell TB, et al. Patched 1 regulates Smoothened by controlling sterol binding to its extracellular cysteine-rich domain. Sci Adv. 2022;8:5563.","journal-title":"Sci Adv"},{"key":"633_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114306","volume":"236","author":"S Kovachka","year":"2022","unstructured":"Kovachka S, Malloci G, Simsir M, et al. Inhibition of the drug efflux activity of Ptch1 as a promising strategy to overcome chemotherapy resistance in cancer cells. Eur J Med Chem. 2022;236:114306.","journal-title":"Eur J Med Chem"},{"key":"633_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143410","author":"AN Sigafoos","year":"2021","unstructured":"Sigafoos AN, Paradise BD, Fernandez-Zapico ME. Hedgehog\/GLI signaling pathway: transduction, regulation, and implications for disease. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13143410.","journal-title":"Cancers (Basel)"},{"key":"633_CR49","doi-asserted-by":"publisher","first-page":"1497708","DOI":"10.3389\/fphar.2025.1497708","volume":"16","author":"B Wang","year":"2025","unstructured":"Wang B, Zhao K, Xian N, et al. Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database. Front Pharmacol. 2025;16:1497708.","journal-title":"Front Pharmacol"},{"key":"633_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117302","volume":"244","author":"S Liao","year":"2020","unstructured":"Liao S, Floyd C, Verratti N, Leung L, Wu C. Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations. Life Sci. 2020;244:117302.","journal-title":"Life Sci"},{"key":"633_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106858","volume":"195","author":"L Maresca","year":"2023","unstructured":"Maresca L, Crivaro E, Migliorini F, et al. Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth. Pharmacol Res. 2023;195:106858.","journal-title":"Pharmacol Res"},{"key":"633_CR52","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/0929866530666230124113639","volume":"30","author":"Z Wang","year":"2023","unstructured":"Wang Z, Song W. Gelsolin inhibits the proliferation of colon cancer cells by enhancing the expression of TNFR2\/CASP10 as a death receptor pathway. Protein Pept Lett. 2023;30:214\u201320.","journal-title":"Protein Pept Lett"},{"key":"633_CR53","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.2174\/1568026620999201027224229","volume":"20","author":"K Miyano","year":"2020","unstructured":"Miyano K, Manabe S, Komatsu A, et al. The G protein signal-biased compound TRV130; structures, its site of action and clinical studies. Curr Top Med Chem. 2020;20:2822\u20139.","journal-title":"Curr Top Med Chem"},{"key":"633_CR54","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.62347\/SCLS3277","volume":"14","author":"R Wang","year":"2024","unstructured":"Wang R, Li S, Wang B, Wang G, Zheng H. Impact of opioids and mu-opioid receptors on oncologic metastasis. Am J Cancer Res. 2024;14:4236\u201347.","journal-title":"Am J Cancer Res"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-026-00633-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00633-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-026-00633-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:48:23Z","timestamp":1781632103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41065-026-00633-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["633"],"URL":"https:\/\/doi.org\/10.1186\/s41065-026-00633-6","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the ethical review committee of Quanzhou first hospital Affiliated to Fujian Medical University. Written informed consent was obtained from all enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Patients agree to participate in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}